Health Care [ 6/12 ] | Pharmaceuticals [ 17/73 ]
NASDAQ | Common Stock
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia.
It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA.
Scilex Holding Company is headquartered in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -7.42 Increased by +19.07% | -0.12 Decreased by -6.08 K% |
| May 14, 25 | -2.26 Decreased by -841.67% | -0.12 Decreased by -1.78 K% |
| Mar 31, 25 | -2.98 Decreased by -1.09 K% | -0.14 Decreased by -2.03 K% |
| Nov 27, 24 | -1.36 Decreased by -116.67% | -3.50 Increased by +61.00% |
| Aug 28, 24 | -9.17 Decreased by -40.20% | -4.90 Decreased by -87.11% |
| May 13, 24 | -0.24 Decreased by -9.09% | -0.10 Decreased by -140.00% |
| Mar 12, 24 | -0.25 Decreased by -92.31% | -0.23 Decreased by -8.70% |
| Nov 13, 23 | -0.63 Decreased by -6.20 K% | -0.17 Decreased by -270.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 9.90 M Decreased by -39.55% | -86.06 M Decreased by -129.00% | Decreased by -869.65% Decreased by -278.80% |
| Mar 31, 25 | 5.00 M Decreased by -54.02% | -26.08 M Decreased by -6.99% | Decreased by -521.18% Decreased by -132.70% |
| Dec 31, 24 | 14.90 M Increased by +10.68% | -6.46 M Increased by +69.81% | Decreased by -43.36% Increased by +72.73% |
| Sep 30, 24 | 14.44 M Increased by +42.69% | -4.39 M Increased by +87.65% | Decreased by -30.40% Increased by +91.34% |
| Jun 30, 24 | 16.37 M Increased by +30.11% | -37.58 M Decreased by -41.03% | Decreased by -229.58% Decreased by -8.39% |
| Mar 31, 24 | 10.88 M Increased by +2.85% | -24.38 M Increased by +20.73% | Decreased by -223.97% Increased by +22.93% |
| Dec 31, 23 | 13.46 M Increased by +12.95% | -21.40 M Decreased by -19.66% | Decreased by -158.97% Decreased by -5.94% |
| Sep 30, 23 | 10.12 M Decreased by -11.07% | -35.53 M Decreased by -265.24% | Decreased by -351.18% Decreased by -285.82% |